Payment overview · 2025
General Payments
$569.44
35 reported records · 9 companies
Healthcare provider profile · identity verified
Michael D Bernardon, MD
Allopathic & Osteopathic Physicians|Family Medicine · WEST CHESTER, OH · NPI 1932178316
Verified facts
What the public records show
CMS Open Payments records show Michael D Bernardon, MD received $569.44 in general payments during 2025 across 35 reported records.
ABBVIE INC. accounted for 40.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trelegy Ellipta by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $232.21 | 40.8% | 20 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $107.87 | 18.9% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $65.44 | 11.5% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $37.22 | 6.5% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $33.44 | 5.9% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $31.18 | 5.5% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $24.26 | 4.3% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $22.85 | 4.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.97 | 2.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $569.44 | 35 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $197.22 | 16 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $194.08 | 15 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $84.81 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $84.81 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $65.44 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $65.44 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $37.22 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $33.44 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $31.34 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $31.18 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $24.26 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $23.06 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $22.85 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.97 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.97 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 65 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
68 | 22 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
65 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
100 | 23 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
20 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 728 | 218 |
| Levothyroxine Sodium | Levothyroxine Sodium | 556 | 167 |
| Lisinopril | Lisinopril | 445 | 134 |
| Amlodipine Besylate | Amlodipine Besylate | 380 | 115 |
| Metformin Hcl | Metformin Hcl | 285 | 73 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 244 | 79 |
| Omeprazole | Omeprazole | 238 | 79 |
| Gabapentin | Gabapentin | 213 | 44 |
| Zolpidem Tartrate | Zolpidem Tartrate | 199 | 46 |
| Glipizide Er | Glipizide | 198 | 62 |
| Pantoprazole Sodium | Pantoprazole Sodium | 174 | 53 |
| Alprazolam | Alprazolam | 170 | 44 |
| Trazodone Hcl | Trazodone Hcl | 167 | 39 |
| Tamsulosin Hcl | Tamsulosin Hcl | 159 | 48 |
| Methylprednisolone | Methylprednisolone | 150 | 116 |
| Escitalopram Oxalate | Escitalopram Oxalate | 148 | 31 |
| Furosemide | Furosemide | 145 | 52 |
| Metoprolol Tartrate | Metoprolol Tartrate | 143 | 40 |
| Metoprolol Succinate | Metoprolol Succinate | 142 | 50 |
| Simvastatin | Simvastatin | 140 | 48 |
| Sertraline Hcl | Sertraline Hcl | 134 | 44 |
| Losartan Potassium | Losartan Potassium | 126 | 44 |
| Hydrochlorothiazide | Hydrochlorothiazide | 114 | 46 |
| Metformin Hcl Er | Metformin Hcl | 113 | 38 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 103 | 41 |
| Valsartan | Valsartan | 101 | 40 |
| Eliquis | Apixaban | 100 | 23 |
| Prednisone | Prednisone | 98 | 63 |
| Allopurinol | Allopurinol | 94 | 30 |
| Atenolol | Atenolol | 89 | 28 |
| Azithromycin | Azithromycin | 88 | 63 |
| Montelukast Sodium | Montelukast Sodium | 88 | 27 |
| Celecoxib | Celecoxib | 83 | 29 |
| Methocarbamol | Methocarbamol | 82 | 21 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 82 | 57 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 80 | 27 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 79 | 26 |
| Fluoxetine Hcl | Fluoxetine Hcl | 77 | 21 |
| Tramadol Hcl | Tramadol Hcl | 75 | 24 |
| Lorazepam | Lorazepam | 73 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 72 | 30 |
| Meloxicam | Meloxicam | 72 | 21 |
| Diazepam | Diazepam | 70 | 22 |
| Pregabalin | Pregabalin | 70 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 68 | 42 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 68 | 22 |
| Synthroid | Levothyroxine Sodium | 68 | 22 |
| Clonazepam | Clonazepam | 67 | 14 |
| Ozempic | Semaglutide | 65 | 15 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 62 | 25 |
| Amoxicillin | Amoxicillin | 61 | 54 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 59 | 16 |
| Alendronate Sodium | Alendronate Sodium | 58 | 19 |
| Potassium Chloride | Potassium Chloride | 58 | 18 |
| Carvedilol | Carvedilol | 57 | 13 |
| Torsemide | Torsemide | 53 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 50 | 16 |
| Finasteride | Finasteride | 48 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 46 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 43 | 38 |
| Clopidogrel | Clopidogrel Bisulfate | 43 | 16 |
| Donepezil Hcl | Donepezil Hcl | 40 | suppressed |
| Xarelto | Rivaroxaban | 40 | 11 |
| Famotidine | Famotidine | 39 | 16 |
| Fenofibrate | Fenofibrate | 39 | 11 |
| Warfarin Sodium | Warfarin Sodium | 39 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 37 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 37 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 36 | 12 |
| Ezetimibe | Ezetimibe | 35 | 11 |
| Jardiance | Empagliflozin | 35 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 35 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 34 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 33 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 33 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 33 | 24 |
| Lovastatin | Lovastatin | 32 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 32 | suppressed |
| Fluconazole | Fluconazole | 31 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 30 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 30 | suppressed |
| Nabumetone | Nabumetone | 30 | 16 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 30 | 13 |
| Spironolactone | Spironolactone | 30 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 30 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 29 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 28 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 28 | suppressed |
| Bupropion Xl | Bupropion Hcl | 28 | 11 |
| Levofloxacin | Levofloxacin | 28 | 25 |
| Estradiol | Estradiol | 27 | suppressed |
| Ibuprofen | Ibuprofen | 27 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 26 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 26 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 17 |
| Glipizide | Glipizide | 25 | suppressed |
| Ketoconazole | Ketoconazole | 25 | 19 |
| Trulicity | Dulaglutide | 25 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Clarithromycin | Clarithromycin | 24 | 17 |
| Oxycodone Hcl | Oxycodone Hcl | 24 | 11 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 23 | suppressed |
| Entresto | Sacubitril/Valsartan | 23 | suppressed |
| Mupirocin | Mupirocin | 23 | 17 |
| Ondansetron Hcl | Ondansetron Hcl | 23 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 22 | suppressed |
| Hydrocortisone | Hydrocortisone | 22 | 13 |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Topiramate | Topiramate | 22 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 21 | suppressed |
| Baclofen | Baclofen | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Mirtazapine | Mirtazapine | 21 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 20 | 20 |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | 11 |
| Mounjaro | Tirzepatide | 19 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 18 | suppressed |
| Cephalexin | Cephalexin | 17 | 16 |
| Nitroglycerin | Nitroglycerin | 17 | 12 |
| Nystatin | Nystatin | 17 | 11 |
| Primidone | Primidone | 17 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 16 | 14 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Januvia | Sitagliptin Phosphate | 16 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 16 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | suppressed |
| Klor-Con M20 | Potassium Chloride | 15 | suppressed |
| Levemir Flexpen | Insulin Detemir | 15 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $569.44 · 35 records | ABBVIE INC. | Cologuard Collection Kit, FREESTYLE LIBRE 3, LEQVIO, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, Veozah, Wegovy, ZAVZPRET | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error